Skip to main content
Fig. 3 | BMC Medicine

Fig. 3

From: Metabolic systems approaches update molecular insights of clinical phenotypes and cardiovascular risk in patients with homozygous familial hypercholesterolemia

Fig. 3

Pathway enrichment and clinical phenotype-correlation analyses of metabolic signatures. a Expression level-based quantitative pathway enrichment analysis of the differentiated metabolites that distinguished the HoFH group from the non-FH and HeFH groups. The bubble size refers to the enrichment ratio of the pathway and the color represents the natural log of the FDR-adjusted P value. b IPA-based functional network between the HoFH-associated metabolites and enriched biological pathways/diseases. Rectangles, nodes, and edges represent metabolites, functional pathways/diseases, and associations, respectively. c Correlation plot depicting the correlation of clinical lipids with corneal arcus/xanthomas, supravalvular aortic stenosis, and valvular aortic stenosis, using regression analyses (FDR-adjusted *P < 0.05; FDR-adjusted **P < 0.01). d–f Correlation plot depicting the relation of metabolomic features with corneal arcus/xanthomas, supravalvular aortic stenosis, or valvular aortic stenosis (FDR-adjusted *P < 0.05; FDR-adjusted **P < 0.01). LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, Lp(a) lipoprotein (a), ApoA1 apolipoprotein A1, ApoB apolipoprotein B. Other abbreviations are shown in Fig. 1

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us